Research Article
BibTex RIS Cite

The Combination Effect of Ferulic Acid and Gemcitabine on Expression of Genes Related Apoptosis and Metastasis in PC-3 Prostate Cancer Cells

Year 2018, Volume: 77 Issue: 1, 32 - 37, 22.06.2018

Abstract

DOI:
10.26650/EuroJBiol.2018.0003


Objective: Prostate cancer is the second
most common cause of cancer-related deaths in men. Nowadays, new treatment
approaches have been tested for cancer therapy including natural compounds with
low toxicity. Ferulic acid (FA) is known as an abundant phenolic compound found
in various fruits and vegetables. As a potent antioxidant, the anticarcinogenic
effect of FA has been demonstrated in various cancer cell lines. The objective
of this study was to investigate the combined effect of FA and gemcitabine on
apoptosis and metastasis in PC-3 human prostate cancer cell lines.



Materials and Methods: Cell viability was
determined using the XTT method after the cells were treated with gemcitabine
or FA and gemcitabine. According to the results of cytotoxicity assays, PC-3
cells were treated with <IC50 doses of combination (200 μM FA and 35 μM
gemcitabine) and IC50 dose of gemcitabine. Expressions of genes that are
important in apoptosis and metastasis pathways were evaluated in dose and
control groups by qPCR.



Results: According to the results, the combination
of FA and gemcitabine affected the expression of more genes in apoptosis and
metastasis with a higher fold change compared with the single treatment of
gemcitabine in PC-3 human prostate cancer cell lines.



Conclusion: Our study indicates that FA can
be an effective part of the combination treatments.

References

  • 1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016; 66(1):7-30.
  • 2. Trewartha D, Carter K. Advances in prostate cancer treatment. Nat Rev Drug Discov 2013; 12(11):823-4.
  • 3. Scher HI, Leibel SA, Fuks Z, Cordon-Cardo C, Scardino PT. Cancers of the prostate. DeVita VT Jr, Hellman S, Rosenberg SA, editors. 7th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005.
  • 4. Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med 2008; 148(6):435-48.
  • 5. Moe EL, Chadd J, McDonagh M, Valtonen M, Horner-Johnson W, Eden KB, el al. Exercise interventions for prostate cancer survivors receiving hormone therapy: Systematic review. Translational Journal of the ACSM 2017; 2(1):1-9.
  • 6. Botrel TE, Clark O, Lima Pompeo AC, Horta Bretas FF, Sadi MV, Ferreira U, et al. Efficacy and safety of combined androgen deprivation therapy (ADT) and docetaxel compared with ADT alone for metastatic hormone-naive prostate cancer: A systematic review and meta-analysis. PLoS One 2016; 11(6):e0157660.
  • 7. Newman DJ, Cragg GM. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod 2012; 75(3):311-35.
  • 8. Safe S, Kasiappan R. Natural products as mechanism-based anticancer agents: Sp transcription factors as targets. Phytother Res 2016; 30(11):1723-32. 9. Mancuso C, Santangelo R. Ferulic acid: pharmacological and toxicological aspects. Food Chem Toxicol 2014; 65:185-95.
  • 10. Ou S, Kwok KC. Ferulic acid: pharmaceutical functions, preparation and applications in foods. J. Sci. Food. Agric 2004; 84:1261-9.
  • 11. Trombino S, Serini S, Di Nicuolo F, Celleno L, Andò S, Picci N, et al. Antioxidant effect of ferulic acid in isolated membranes and intact cells: synergistic interactions with alpha-tocopherol, beta-carotene, and ascorbic acid. J Agric Food Chem 2004; 52(8):2411-20.
  • 12. Borges A, Ferreira C, Saavedra MJ, Simões M. Antibacterial activity and mode of action of ferulic and gallic acids against pathogenic bacteria. Microb Drug Resist 2013; 19(4):256-65.
  • 13. Zhu H, Liang QH, Xiong XG, Chen J, Wu D, Wang Y, et al. Anti-inflammatory effects of the bioactive compound ferulic acid contained in Oldenlandia diffusa on collagen-induced arthritis in rats. Evid Based Complement Alternat Medn 2014; 2014:573801.
  • 14. Hong Q, Ma ZC, Huang H, Wang YG, Tan HL, Xiao CR, et al. Antithrombotic activities of ferulic acid via intracellular cyclic nucleotide signaling. Eur J Pharmacol 2016; 777:1-8.
  • 15. Shahidi F, Chandrasekara A. Hydroxycinnamates and their in vitro and in vivo antioxidant activities. Phytochem Rev 2010; 9(1):147–170.
  • 16. Serafim TL, Carvalho FS, Marques MP, Calheiros R, Silva T, Garrido J, et al. Lipophilic caffeic and ferulic acid derivatives presenting cytotoxicity against human breast cancer cells. Chem Res Toxicol 2011; 24(5):763-74.
  • 17. Thakkar A, Chenreddy S, Wang J, Prabhu S. Ferulic acid combined with aspirin demonstrates chemopreventive potential towards pancreatic cancer when delivered using chitosan-coated solid-lipid nanoparticles. Cell Biosci 2015; 5:46.
  • 18. Eroğlu C, Seçme M, Bağcı G, Dodurga Y. Assessment of the anticancer mechanism of ferulic acid via cell cycle and apoptotic pathways in human prostate cancer cell lines. Tumour Biol 2015; 36(12):9437-46.
  • 19. Fong Y, Tang CC, Hu HT, Fang HY, Chen BH, Wu CY, et al. Inhibitory effect of trans-ferulic acid on proliferation and migration of human lung cancer cells accompanied with increased endogenous reactive oxygen species and β-catenin instability. Chin Med 2016;11:45.
  • 20. Wang T, Gong X, Jiang R, Li H, Du W, Kuang G. Ferulic acid inhibits proliferation and promotes apoptosis via blockage of PI3K/Akt pathway in osteosarcoma cell. Am J Transl Res 2016; 8(2):968-80.
  • 21. Choi YE, Park E. Ferulic acid in combination with PARP inhibitor sensitizes breast cancer cells as chemotherapeutic strategy. Biochem Biophys Res Commun 2015; 458(3):520-4.
  • 22. Kalimuthu S, Se-Kwon K. Cell survival and apoptosis signaling as therapeutic target for cancer: marine bioactive compounds. Int J Mol Sci 2013; 14(2):2334-54.
  • 23. Elmore S. Apoptosis: A review of programmed cell death. Toxicol Pathol 2007; 35(4):495-516.
  • 24. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006;1 2(20 Pt 2):6243-9.
  • 25. Sturge J, Caley MP, Waxman J. Bone metastasis in prostate cancer: Emerging therapeutic strategies. Nat Rev Clin Oncol 2011;8(6):357-68.
  • 26. Guan X. Cancer metastases: Cehallenges and opportunities. Acta Pharm Sin B 2015; 5(5):402-18.
  • 27. Jiang WG, Sanders AJ, Katoh M, Ungefroren H, Gieseler F, Prince M, et al. Tissue invasion and metastasis: Molecular, biological and clinical perspectives. Semin Cancer Biol 2015; 35:244-75.
  • 28. Wong A, Soo RA, Yong WP, Innocenti F. Clinical pharmacology and pharmacogenetics of gemcitabine. Drug Metab Rev 2009; 41(2):77-88.
  • 29. Huang CY, Chang YJ, Luo SD, Uyanga B, Lin FY, Tai CJ, et al. Maspin mediates the gemcitabine sensitivity of hormone-independent prostate cancer. Tumour Biol 2016; 37(3):4075-82.
  • 30. Di Lorenzo G, Autorino R, Giuliano M, Morelli E, Giordano A, Napodano G, et al. Phase II trial of gemcitabine, prednisone, and zoledronic acid in pretreated patients with hormone refractory prostate cancer. Urology 2007; 69(2):347-51.
  • 31. Lee JL, Ahn JH, Choi MK, Kim Y, Hong SW, Lee KH, et al. Gemcitabine-oxaliplatin plus prednisolone is active in patients with castration-resistant prostate cancer for whom docetaxel-based chemotherapy failed. Br J Cancer 2014; 110(10):2472-8.
  • 32. Reddy L, Odhav B, Bhoola KD. Natural products for cancer prevention: A global perspective. Pharmacol Ther 2003; 99:1–13.
  • 33. Liu RH. Health-promoting components of fruits and vegetables in the diet. Adv Nutr 2013; 4(3):384S-92S.
  • 34. Arts IC, Hollman PC. Polyphenols and disease risk in epidemiologic studies. Am J Clin Nutr 2005; 81:317S–25S.
  • 35. Russell W, Duthie G. Plant secondary metabolites and gut health: the case for phenolic acids. Proc Nutr Soc 2011; 70:389–96.
  • 36. Syed DN, Khan N, Afaq F, Mukhtar H. Chemoprevention of prostate cancer through dietary agents: progress and promise. Cancer Epidemiol Biomarkers Prev 2007; 16(11):2193-203.
  • 37. Singh CK, George J, Ahmad N.Resveratrol-based combinatorial strategies for cancer management. Ann N Y Acad Sci 2013; 1290:113-21.
  • 38. Anantharaju PG, Gowda PC, Vimalambike MG, Madhunapantula SV. An overview on the role of dietary phenolics for the treatment of cancers. Nutr J 2016; 15(1):99.
  • 39. Chowdhury S, Ghosh S, Rashid K, Sil PC. Deciphering the role of ferulic acid against streptozotocin-induced cellular stress in the cardiac tissue of diabetic rats. Food Chem Toxicol 2016; 97:187-98.
  • 40. Li H, Wang Y, Fan R, Lv H, Sun H, Xie H, et al. The effects of ferulic acid on the pharmacokinetics of warfarin in rats after biliary drainage. Drug Des Devel Ther 2016; 10: 2173–80.
  • 41. Pan Y, Zhao G, Cai Z, Chen F, Xu D, Huang S, et al. Synergistic effect of ferulic acid and Z-Ligustilide, major components of A. sinensis, on regulating cold-sensing protein TRPM8 and TPRA1 in vitro. Evid Based Complement Alternat Med 2016; 2016: 3160247.
  • 42. Li G, Ruan L, Chen R, Wang R, Xie X, Zhang M, et al. Synergistic antidepressant-like effect of ferulic acid in combination with piperine: involvement of monoaminergic system. Metab Brain Dis 2015; 30(6):1505-14.
  • 43. Canturk Z. Evaluation of synergistic anticandidal and apoptotic effects of ferulic acid and caspofungin against Candida albicans. J Food Drug Anal 2017; 1-5.
  • 44. Rahman H, Upaganlawar A, Upasani C. Protective effect of ferulic ccid alone and in combination with ascorbic acid on aniline induced spleen toxicity. Ann Pharmacol Pharm 2017; 2(1): 1012.
  • 45. Eitsuka T, Tatewaki N, Nishida H, Kurata T, Nakagawa K, Miyazawa T. Synergistic inhibition of cancer cell proliferation with a combination of δ-tocotrienol and ferulic acid. Biochem Biophys Res Commun 2014;453(3):606-11.
  • 46. Eitsuka T, Tatewaki N, Nishida H, Nakagawa K, Miyazawa T. A Combination of δ-tocotrienol and ferulic acid synergistically inhibits telomerase activity in DLD-1 human colorectal adenocarcinoma cells. J Nutr Sci Vitaminol (Tokyo) 2016; 62(5):281-7.
  • 47. Goldar S, Khaniani MS, Derakhshan SM, Baradaran B. Molecular mechanisms of apoptosis and roles in cancer development and treatment. Asian Pac J Cancer Prev 2015; 16(6):2129-44.
  • 48. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009; 119(6):1420-8.
  • 49. Tsai JH, Yang J. Epithelial-mesenchymal plasticity in carcinoma metastasis. Genes Dev 2013; 27(20):2192-206.
  • 50. Jacob A, Prekeris R. The regulation of MMP targeting to invadopodia during cancer metastasis. Front Cell Dev Biol 2015;3:4.

The Combination Effect of Ferulic Acid and Gemcitabine on Expression of Genes Related Apoptosis and Metastasis in PC-3 Prostate Cancer Cells

Year 2018, Volume: 77 Issue: 1, 32 - 37, 22.06.2018

Abstract

DOI: 10.26650/EuroJBiol.2018.0003


Objective: Prostate cancer is the second most common cause of cancer-related deaths in men. Nowadays, new treatment approaches have been tested for cancer therapy including natural compounds with low toxicity. Ferulic acid (FA) is known as an abundant phenolic compound found in various fruits and vegetables. As a potent antioxidant, the anticarcinogenic effect of FA has been demonstrated in various cancer cell lines. The objective of this study was to investigate the combined effect of FA and gemcitabine on apoptosis and metastasis in PC-3 human prostate cancer cell lines.

Materials and Methods: Cell viability was determined using the XTT method after the cells were treated with gemcitabine or FA and gemcitabine. According to the results of cytotoxicity assays, PC-3 cells were treated with <IC50 doses of combination (200 μM FA and 35 μM gemcitabine) and IC50 dose of gemcitabine. Expressions of genes that are important in apoptosis and metastasis pathways were evaluated in dose and control groups by qPCR.

Results: According to the results, the combination of FA and gemcitabine affected the expression of more genes in apoptosis and metastasis with a higher fold change compared with the single treatment of gemcitabine in PC-3 human prostate cancer cell lines.

Conclusion: Our study indicates that FA can be an effective part of the combination treatments.

References

  • 1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016; 66(1):7-30.
  • 2. Trewartha D, Carter K. Advances in prostate cancer treatment. Nat Rev Drug Discov 2013; 12(11):823-4.
  • 3. Scher HI, Leibel SA, Fuks Z, Cordon-Cardo C, Scardino PT. Cancers of the prostate. DeVita VT Jr, Hellman S, Rosenberg SA, editors. 7th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005.
  • 4. Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med 2008; 148(6):435-48.
  • 5. Moe EL, Chadd J, McDonagh M, Valtonen M, Horner-Johnson W, Eden KB, el al. Exercise interventions for prostate cancer survivors receiving hormone therapy: Systematic review. Translational Journal of the ACSM 2017; 2(1):1-9.
  • 6. Botrel TE, Clark O, Lima Pompeo AC, Horta Bretas FF, Sadi MV, Ferreira U, et al. Efficacy and safety of combined androgen deprivation therapy (ADT) and docetaxel compared with ADT alone for metastatic hormone-naive prostate cancer: A systematic review and meta-analysis. PLoS One 2016; 11(6):e0157660.
  • 7. Newman DJ, Cragg GM. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod 2012; 75(3):311-35.
  • 8. Safe S, Kasiappan R. Natural products as mechanism-based anticancer agents: Sp transcription factors as targets. Phytother Res 2016; 30(11):1723-32. 9. Mancuso C, Santangelo R. Ferulic acid: pharmacological and toxicological aspects. Food Chem Toxicol 2014; 65:185-95.
  • 10. Ou S, Kwok KC. Ferulic acid: pharmaceutical functions, preparation and applications in foods. J. Sci. Food. Agric 2004; 84:1261-9.
  • 11. Trombino S, Serini S, Di Nicuolo F, Celleno L, Andò S, Picci N, et al. Antioxidant effect of ferulic acid in isolated membranes and intact cells: synergistic interactions with alpha-tocopherol, beta-carotene, and ascorbic acid. J Agric Food Chem 2004; 52(8):2411-20.
  • 12. Borges A, Ferreira C, Saavedra MJ, Simões M. Antibacterial activity and mode of action of ferulic and gallic acids against pathogenic bacteria. Microb Drug Resist 2013; 19(4):256-65.
  • 13. Zhu H, Liang QH, Xiong XG, Chen J, Wu D, Wang Y, et al. Anti-inflammatory effects of the bioactive compound ferulic acid contained in Oldenlandia diffusa on collagen-induced arthritis in rats. Evid Based Complement Alternat Medn 2014; 2014:573801.
  • 14. Hong Q, Ma ZC, Huang H, Wang YG, Tan HL, Xiao CR, et al. Antithrombotic activities of ferulic acid via intracellular cyclic nucleotide signaling. Eur J Pharmacol 2016; 777:1-8.
  • 15. Shahidi F, Chandrasekara A. Hydroxycinnamates and their in vitro and in vivo antioxidant activities. Phytochem Rev 2010; 9(1):147–170.
  • 16. Serafim TL, Carvalho FS, Marques MP, Calheiros R, Silva T, Garrido J, et al. Lipophilic caffeic and ferulic acid derivatives presenting cytotoxicity against human breast cancer cells. Chem Res Toxicol 2011; 24(5):763-74.
  • 17. Thakkar A, Chenreddy S, Wang J, Prabhu S. Ferulic acid combined with aspirin demonstrates chemopreventive potential towards pancreatic cancer when delivered using chitosan-coated solid-lipid nanoparticles. Cell Biosci 2015; 5:46.
  • 18. Eroğlu C, Seçme M, Bağcı G, Dodurga Y. Assessment of the anticancer mechanism of ferulic acid via cell cycle and apoptotic pathways in human prostate cancer cell lines. Tumour Biol 2015; 36(12):9437-46.
  • 19. Fong Y, Tang CC, Hu HT, Fang HY, Chen BH, Wu CY, et al. Inhibitory effect of trans-ferulic acid on proliferation and migration of human lung cancer cells accompanied with increased endogenous reactive oxygen species and β-catenin instability. Chin Med 2016;11:45.
  • 20. Wang T, Gong X, Jiang R, Li H, Du W, Kuang G. Ferulic acid inhibits proliferation and promotes apoptosis via blockage of PI3K/Akt pathway in osteosarcoma cell. Am J Transl Res 2016; 8(2):968-80.
  • 21. Choi YE, Park E. Ferulic acid in combination with PARP inhibitor sensitizes breast cancer cells as chemotherapeutic strategy. Biochem Biophys Res Commun 2015; 458(3):520-4.
  • 22. Kalimuthu S, Se-Kwon K. Cell survival and apoptosis signaling as therapeutic target for cancer: marine bioactive compounds. Int J Mol Sci 2013; 14(2):2334-54.
  • 23. Elmore S. Apoptosis: A review of programmed cell death. Toxicol Pathol 2007; 35(4):495-516.
  • 24. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006;1 2(20 Pt 2):6243-9.
  • 25. Sturge J, Caley MP, Waxman J. Bone metastasis in prostate cancer: Emerging therapeutic strategies. Nat Rev Clin Oncol 2011;8(6):357-68.
  • 26. Guan X. Cancer metastases: Cehallenges and opportunities. Acta Pharm Sin B 2015; 5(5):402-18.
  • 27. Jiang WG, Sanders AJ, Katoh M, Ungefroren H, Gieseler F, Prince M, et al. Tissue invasion and metastasis: Molecular, biological and clinical perspectives. Semin Cancer Biol 2015; 35:244-75.
  • 28. Wong A, Soo RA, Yong WP, Innocenti F. Clinical pharmacology and pharmacogenetics of gemcitabine. Drug Metab Rev 2009; 41(2):77-88.
  • 29. Huang CY, Chang YJ, Luo SD, Uyanga B, Lin FY, Tai CJ, et al. Maspin mediates the gemcitabine sensitivity of hormone-independent prostate cancer. Tumour Biol 2016; 37(3):4075-82.
  • 30. Di Lorenzo G, Autorino R, Giuliano M, Morelli E, Giordano A, Napodano G, et al. Phase II trial of gemcitabine, prednisone, and zoledronic acid in pretreated patients with hormone refractory prostate cancer. Urology 2007; 69(2):347-51.
  • 31. Lee JL, Ahn JH, Choi MK, Kim Y, Hong SW, Lee KH, et al. Gemcitabine-oxaliplatin plus prednisolone is active in patients with castration-resistant prostate cancer for whom docetaxel-based chemotherapy failed. Br J Cancer 2014; 110(10):2472-8.
  • 32. Reddy L, Odhav B, Bhoola KD. Natural products for cancer prevention: A global perspective. Pharmacol Ther 2003; 99:1–13.
  • 33. Liu RH. Health-promoting components of fruits and vegetables in the diet. Adv Nutr 2013; 4(3):384S-92S.
  • 34. Arts IC, Hollman PC. Polyphenols and disease risk in epidemiologic studies. Am J Clin Nutr 2005; 81:317S–25S.
  • 35. Russell W, Duthie G. Plant secondary metabolites and gut health: the case for phenolic acids. Proc Nutr Soc 2011; 70:389–96.
  • 36. Syed DN, Khan N, Afaq F, Mukhtar H. Chemoprevention of prostate cancer through dietary agents: progress and promise. Cancer Epidemiol Biomarkers Prev 2007; 16(11):2193-203.
  • 37. Singh CK, George J, Ahmad N.Resveratrol-based combinatorial strategies for cancer management. Ann N Y Acad Sci 2013; 1290:113-21.
  • 38. Anantharaju PG, Gowda PC, Vimalambike MG, Madhunapantula SV. An overview on the role of dietary phenolics for the treatment of cancers. Nutr J 2016; 15(1):99.
  • 39. Chowdhury S, Ghosh S, Rashid K, Sil PC. Deciphering the role of ferulic acid against streptozotocin-induced cellular stress in the cardiac tissue of diabetic rats. Food Chem Toxicol 2016; 97:187-98.
  • 40. Li H, Wang Y, Fan R, Lv H, Sun H, Xie H, et al. The effects of ferulic acid on the pharmacokinetics of warfarin in rats after biliary drainage. Drug Des Devel Ther 2016; 10: 2173–80.
  • 41. Pan Y, Zhao G, Cai Z, Chen F, Xu D, Huang S, et al. Synergistic effect of ferulic acid and Z-Ligustilide, major components of A. sinensis, on regulating cold-sensing protein TRPM8 and TPRA1 in vitro. Evid Based Complement Alternat Med 2016; 2016: 3160247.
  • 42. Li G, Ruan L, Chen R, Wang R, Xie X, Zhang M, et al. Synergistic antidepressant-like effect of ferulic acid in combination with piperine: involvement of monoaminergic system. Metab Brain Dis 2015; 30(6):1505-14.
  • 43. Canturk Z. Evaluation of synergistic anticandidal and apoptotic effects of ferulic acid and caspofungin against Candida albicans. J Food Drug Anal 2017; 1-5.
  • 44. Rahman H, Upaganlawar A, Upasani C. Protective effect of ferulic ccid alone and in combination with ascorbic acid on aniline induced spleen toxicity. Ann Pharmacol Pharm 2017; 2(1): 1012.
  • 45. Eitsuka T, Tatewaki N, Nishida H, Kurata T, Nakagawa K, Miyazawa T. Synergistic inhibition of cancer cell proliferation with a combination of δ-tocotrienol and ferulic acid. Biochem Biophys Res Commun 2014;453(3):606-11.
  • 46. Eitsuka T, Tatewaki N, Nishida H, Nakagawa K, Miyazawa T. A Combination of δ-tocotrienol and ferulic acid synergistically inhibits telomerase activity in DLD-1 human colorectal adenocarcinoma cells. J Nutr Sci Vitaminol (Tokyo) 2016; 62(5):281-7.
  • 47. Goldar S, Khaniani MS, Derakhshan SM, Baradaran B. Molecular mechanisms of apoptosis and roles in cancer development and treatment. Asian Pac J Cancer Prev 2015; 16(6):2129-44.
  • 48. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009; 119(6):1420-8.
  • 49. Tsai JH, Yang J. Epithelial-mesenchymal plasticity in carcinoma metastasis. Genes Dev 2013; 27(20):2192-206.
  • 50. Jacob A, Prekeris R. The regulation of MMP targeting to invadopodia during cancer metastasis. Front Cell Dev Biol 2015;3:4.
There are 49 citations in total.

Details

Primary Language English
Journal Section Research Articles
Authors

Canan Eroglu This is me

Ebru Avci This is me

Mucahit Secme This is me

Yavuz Dodurga This is me

Hasibe Vural This is me

Ercan Kurar This is me

Publication Date June 22, 2018
Submission Date May 28, 2018
Published in Issue Year 2018 Volume: 77 Issue: 1

Cite

AMA Eroglu C, Avci E, Secme M, Dodurga Y, Vural H, Kurar E. The Combination Effect of Ferulic Acid and Gemcitabine on Expression of Genes Related Apoptosis and Metastasis in PC-3 Prostate Cancer Cells. Eur J Biol. June 2018;77(1):32-37.